Other Clinical Trial - Comparison Three vs Twelve Months of Dual

Status Recruiting

Clinical Trial Summary

This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk™ stent). All participants met the inclusion criteria begin taking aspirin and open-label thienopyridine therapy before index procedure, and will be 1:1 randomized to 3 months or 12 month of DAPT at index procedure.

Clinical Trial Description

This study will recruit 2,446 subjects with stable coronary artery disease in no more than 40 research centers in China. All participants met the inclusion criteria will be 1:1 randomized to 3 months or 12 month of DAPT after implanting Firehawk™ coronary stent.Clinical follow-up will be carried out at 30 days, 3 months, 6 months, 12 months, 18 months, 2 years and 3 years after index procedure.The primary study endpoint is Net Adverse Clinical and Cerebral Events (NACCE), a composite of all-cause death, myocardial infarction (MI), cerebral vascular accident (CVA) and major bleeding (academic research consortium [ARC] definition and GUSTO definition) at 18 months. Subjects that complete of 18 months follow-up will be regarded as having completed the primary endpoint. The secondary study endpoints contain ARC defined stent thrombosis (ST) at all study time-points; NACCE at 30 days,6,12,24 and 36 months of follow-up;major adverse cardiovascular events (MACE),major adverse cardiovascular and cerebral events (MACCE),target lesion revascularization (TLR),target lesion failure(TLF),ST at 30 days,6,12 ,18,24 and 36 months of follow-up; major bleeding at 1, 3, 6, 12 ,18,24 and 36 months of follow up; as well as cost-effective at 18 months of follow-up. ;

Study Design

Related Conditions & MeSH terms

Drug-Eluting Stents
Percutaneous Coronary Intervention

Clinical Trial Details

NCT number	NCT03008083
Study type	Interventional
Source	Shanghai MicroPort Medical (Group) Co., Ltd.
Contact	Ming Zheng, MD
Phone	(86)(10)66513642-6229
Email	mzheng@microport.com
Status	Recruiting
Phase	Phase 4
Start date	January 10, 2019
Completion date	October 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03959072` - Cardiac Cath Lab Staff Radiation Exposure
Not yet recruiting	`NCT05669222` - The FAVOR V AMI Trial	N/A
Recruiting	`NCT04566497` - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.	N/A
Recruiting	`NCT05240781` - Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk	N/A
Recruiting	`NCT03378934` - Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention	Phase 4
Not yet recruiting	`NCT06025071` - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial	Phase 4
Withdrawn	`NCT04043091` - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction	N/A
Completed	`NCT02837744` - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed	`NCT03085823` - The All-comers Sirolimus-coated Balloon European Registry
Completed	`NCT02044146` - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk	Phase 2/Phase 3
Completed	`NCT03131271` - Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention	N/A
Completed	`NCT01135667` - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI	Phase 4
Completed	`NCT01156571` - A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)	Phase 3
Unknown status	`NCT00751491` - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)	Phase 3
Completed	`NCT00725868` - Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention	N/A
Completed	`NCT03708588` - Chewed Versus Integral Pill of Ticagrelor	Phase 4
Completed	`NCT04163393` - R-One Efficiency For PCI Evolution With Robotic Assistance	N/A
Recruiting	`NCT05554588` - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI	N/A
Recruiting	`NCT06080919` - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI).	N/A
Recruiting	`NCT05353140` - LAAO Versus NOAC in Patients With AF and PCI	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms